Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Appointed director

Alector, Inc. (ALEC) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/10/2023 SC 13G/A FIL Ltd reports a 14.5% stake in ALECTOR INC
10/03/2023 4 Romano Gary (Chief Medical Officer) has filed a Form 4 on Alector, Inc.
Txns: Granted 108,000 shares @ $0
Granted 36,000 options to buy @ $6.48, valued at $233.3k
10/03/2023 4 GRASSO MARC (CFO) has filed a Form 4 on Alector, Inc.
Txns: Granted 123,000 shares @ $0
Granted 41,000 options to buy @ $6.48, valued at $265.7k
10/03/2023 4 Kenkare-Mitra Sara (President and Head of R&D) has filed a Form 4 on Alector, Inc.
Txns: Granted 163,600 shares @ $0
Granted 54,500 options to buy @ $6.48, valued at $353.2k
10/03/2023 4 Rosenthal Arnon (CEO) has filed a Form 4 on Alector, Inc.
Txns: Granted 397,600 shares @ $0
Granted 132,500 options to buy @ $6.48, valued at $858.6k
08/24/2023 4 MCGUIRE TERRANCE (10% Owner) has filed a Form 4 on Alector, Inc.
Txns: Disposed of 500,000 shares @ $0
Acquired 6,429 shares @ $0
Acquired 98,533 shares @ $0
Disposed of 98,533 shares @ $0
Acquired 13,133 shares @ $0
08/24/2023 4 Polaris Venture Management Co. VI, L.L.C. (10% Owner) has filed a Form 4 on Alector, Inc.
Txns: Disposed of 500,000 shares @ $0
Acquired 98,533 shares @ $0
Disposed of 98,533 shares @ $0
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Alector Reports Second Quarter 2023 Financial Results and Provides Business Update Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer’s Association International Conference Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA $630.0 million in cash, cash equivalents and investments provide runway through 2025; revenue and expense guidance updated for 2023 Management to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT South San Francisco, Calif.,"
06/05/2023 4 Kenkare-Mitra Sara (President and Head of R&D) has filed a Form 4 on Alector, Inc.
Txns: Sold 4,092 shares @ $6.9037, valued at $28.2k
06/05/2023 4 GRASSO MARC (CFO) has filed a Form 4 on Alector, Inc.
Txns: Sold 1,050 shares @ $6.9037, valued at $7.2k
06/05/2023 4 Romano Gary (Chief Medical Officer) has filed a Form 4 on Alector, Inc.
Txns: Sold 2,617 shares @ $6.9037, valued at $18.1k
06/05/2023 4 Rosenthal Arnon (CEO) has filed a Form 4 on Alector, Inc.
Txns: Sold 5,255 shares @ $6.9037, valued at $36.3k
06/01/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/02/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/27/2023 8-K Quarterly results
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 8-K Quarterly results
03/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/03/2023 4 Romano Gary (Chief Medical Officer) has filed a Form 4 on Alector, Inc.
Txns: Sold 2,145 shares @ $8.7082, valued at $18.7k
Sold 3,238 shares @ $8.3179, valued at $26.9k
03/03/2023 4 Kenkare-Mitra Sara (President and Head of R&D) has filed a Form 4 on Alector, Inc.
Txns: Sold 10,124 shares @ $8.3185, valued at $84.2k
03/03/2023 4 GRASSO MARC (CFO) has filed a Form 4 on Alector, Inc.
Txns: Sold 1,291 shares @ $8.3184, valued at $10.7k
03/03/2023 4 Rosenthal Arnon (CEO) has filed a Form 4 on Alector, Inc.
Txns: Sold 5,849 shares @ $8.3178, valued at $48.7k
02/28/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy